Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent *Pseudomonas aeruginosa* vaccine

G. R. BARCLAY, P. L. YAP, D. B. L. McCLELLAND, R. J. JONES*, ELIZABETH A. ROE*, MOIRA C. McCANN†, LISEL R. MICKLE†, AND K. JAMES†

Edinburgh and South-East Scotland Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh, EH3 9HB, *MRC Vaccine Research Laboratories, Birmingham University Medical School, Birmingham, and †Department of Surgery, Edinburgh University, Edinburgh

Summary. Mouse monoclonal antibodies raised by immunisation with a protective antigen extract from *Pseudomonas aeruginosa* serotype 1 varied in immunoglobulin isotype, in passive protective properties against infection by homologous *P. aeruginosa* serotype 1, and in cross-reactions in ELISA against antigen preparations from 15 other *P. aeruginosa* serotypes. All monoclonal antibodies with specificity in ELISA for the immunising antigen gave some degree of protection to mice against lethal infection by the homologous *P. aeruginosa* serotype. The IgG antibodies were more protective than the IgM antibodies.

Introduction

A 16-part polyvalent pseudomonas extract vaccine (PEV) has been used for immunising burned patients against *Pseudomonas aeruginosa* in a prophylactic trial (Jones, 1979). It has also been shown that immunoglobulin from healthy volunteers immunised with PEV conferred passive immunity against pseudomonas septicaemia in severely burned children and in adults at risk from *P. aeruginosa* infection (Roe and Jones, 1983). PEV is composed of equal proportions of cell-wall extracts from each of the 16 international serotypes of *P. aeruginosa*, pseudomonas vaccine antigens 1 to 16 (PVA-1 to PVA-16). The cell-wall extracts are predominantly lipopolysaccharide (Miler et al., 1977). Each elicited serotype-specific antibodies and a variable range of cross-reactive and cross-protective antibodies in mice (Jones and Roe, 1975).

To investigate the mechanism of protection against *P. aeruginosa* by passively transferred antibodies, mouse monoclonal antibodies were raised against one of the cell-wall extracts, PVA-1, extracted from *P. aeruginosa* strain B.U.K.1 (serotype 1). These monoclonal antibodies were tested by ELISA for specificity and titre against the 16 extracts (PVA-1 to PVA-16) comprising PEV. Immunoglobulins in selected anti-pseudomonas clones were isotyped and their protective properties against homologous lethal challenge were determined in a mouse protection test.

Materials and methods

**Bacteria**

*P. aeruginosa* strain B.UK.1 (serotype 1) was isolated from the blood of a septicaemic burned patient at Birmingham Accident Hospital by routine methods (Davis et al., 1969). Strains of the other 15 serotypes of *P. aeruginosa* used for preparing the PVAs incorporated in PEV were isolated from hospital sources in Europe, Asia and Japan. These bacteria were selected because their extracts caused minimal toxic reactions when used as vaccines in mice and rabbits (Miler et al., 1977).

**Extraction of PVA from cell walls**

Suspensions of the 16 serotypes of *P. aeruginosa*, each containing (3-5)×10⁶ viable bacteria/ml, were grown for 16 h in a chemically defined medium and the PVAs were extracted by treatment for 2 min at 37°C with a mixture of 0·01 M EDTA and 0·003 M glycine according to the method of Miler et al. (1977). After mixing at room temperature with an equal volume of formaldehyde 0·6% w/v and positive pressure filtration through a membrane filter (Millipore, HA 0·65 μm), the crude soluble cell-wall extracts were lyophilised.

**Preparation of monoclonal antibodies**

Female 12-week-old BALB/c mice were immunised by three intraperitoneal injections, at weekly intervals, of 250 μg of PVA-1 in 0·3 ml of phosphate-buffered saline (PBS, pH 7·2; Dulbecco "A", Oxoid). Antibody responses to PVAs 1–16 were determined by ELISA on serum obtained one week after the third dose. A mouse with a strong anti-PVA-1 response was immunised intravenously with 250 μg of PVA-1 10 weeks after the third dose, and killed 3 days later to obtain spleen cells. Mouse spleen cells were fused with cells of the NS-1 (NS-1/1-Ag4-1) plasmacytoma cell line (Kohler et al., 1976) by the method of Oi and Herzenberg (1980). Selective and maintenance cultures were essentially as described by Kennett et al. (1979). Hybrids in HAT medium in 96-well culture plates.

Received 13 Feb. 1985; accepted 19 Apr. 1985.
were screened for anti-PVA antibodies. Antibody-positive hybrids were cloned by limiting dilution.

ELISA

PVA stock solutions, 0.1 mg/ml in distilled water, were diluted 1 in 100 in coating buffer (0.1 M carbonate-bicarbonate, pH 9.6) and placed (100 μl/well) in polystyrene 96-well microtitration plates (*"Immulon" M129A, Dynatech, Billingshurst, Kent) for coating overnight at room temperature. All solutions were made in filtered distilled water containing sodium azide 0.1% w/v. Plates were washed with PBS containing Tween-20 0.1% v/v (wash buffer), by an automated plate washer (Titertek "Multiwash", Flow Laboratories, Irvine, Scotland), incubated for a further 4 h at 37°C with bovine serum albumin 3% w/v in PBS (200 μl/well), then washed again, rinsed in distilled water and stored at 4°C until used. Culture supernates and antibodies were diluted in wash buffer containing polyethylene glycol 4% w/v (PEG 4000, Sigma) (dilution buffer). Culture supernates were screened at a 1 in 5 dilution in this buffer, and their titres determined by serial dilution. Volumes of 100 μl/well were incubated for 90 min at 37°C on coated plates, followed by four washes. Bound antibody was detected by the addition of urease-conjugated sheep anti-mouse immunoglobulins (Sera-Lab. Ltd, Crawley Down, Sussex) at a 1 in 200 dilution (100 pl/well) for 90 min at 37°C. Unbound anti-mouse antibody was removed by washing four times. Plates were rinsed four times in distilled water and urease substrate solution (Sera-Lab) was added (100 μl/well). Specific antibody-positive reactions resulted in a change in substrate colour from yellow to blue (Chandler et al., 1982). The degree of reaction was determined after 90 min at 37°C by reading the optical density at 585 nm in an automated ELISA microplate reader (Titertek "Multiscan/MC", Flow Laboratories), and employing untreated substrate as a baseline reading (machine blank).

Immunoglobulin isotypes of monoclonal anti-pseudomonas antibodies were determined by double radial immunodiffusion in agar (Ouchterlony technique) with specific antibodies to each of mouse IgM, IgA, IgG1, IgG2a, IgG2b and IgG3 (Serotech Ltd, Bicester, Oxon). The IgG contents of supernates were measured by a modified Laurell-rocket technique, with known quantities of purified monoclonal IgG of appropriate subclasses as standards (C. Prowse and D.S. Pepper, unpublished). The IgM contents were measured by an anti-mouse IgM ELISA assay with a purified mouse monoclonal IgM as a standard.

Passive protection tests

Groups of five male CBA mice, each weighing c. 25 g, were given intraperitoneal (ip) injections of 1.0 ml of saline dilutions of monoclonal antibody (hybridoma supernates) at 1 in 10, 1 in 50, 1 in 100, 1 in 200, 1 in 400, 1 in 1000, 1 in 2000, 1 in 5000 and 1 in 10 000. Two hours later, mice were challenged ip with 1.0 MLD of *P. aeruginosa* strain B.UK.1 according to previously described methods (Jones et al., 1971). The MLD which killed 5 out of 5 healthy control mice was 5.2 x 10⁶ *P. aeruginosa* B.UK.1. cells in 1 ml of saline. After bacterial challenge, mice were given food and water *ad libitum* and the number of survivors recorded for the next 3 days.

Results

After fusion, 58 out of 153 hybrid cell cultures in selective medium secreted anti-PVA antibodies when screened by ELISA with each of the 16 serotype extracts. All 58 positive cultures secreted antibodies that reacted with the immunising antigen (PVA-1). Five of these 58 cultures also reacted with PVA-2 and PVA-12. A range of hybrids was selected for cloning by limiting dilution in maintenance culture medium. Selections were made of cultures with good growth characteristics and included those producing apparently multispecific (anti-PVA-1, -2 and -12) antibodies and a range of monospecific (anti-PVA-1) antibodies that gave different degrees of reaction in the ELISA screen.

A total of 18 hybrid cell lines secreting anti-PVA antibodies were obtained after cloning and maintenance through successive cultures. Each monoclonal antibody was characterised with regard to specificity for the 16 PVAs in ELISA, to ELISA titres against the antigens to which they showed specificities, to immunoglobulin isotype and to concentration in culture supernate. Each was tested for its capacity to protect mice against lethal challenge with the immunising strain of *P. aeruginosa* serotype 1. The results are summarized in the table. Anti-PVA-2 and anti-PVA-12 titres (not shown) were c. 20 for antibodies with these specificities.

The yield of immunoglobulin in culture supernates ranged from 25 to 94 μg/ml for IgG and from 3.5 to 106 μg/ml for IgM. Of the 18 monoclonal antibodies, 16 were specific for the immunising antigen (PVA-1) alone by ELISA, one had low-titre reactions with PVA-1, PVA-2 and PVA-12, and another had low-titre reactions with PVA-2 and PVA-12 but not with PVA-1. Evidently, with the exception of clone no. 4, the majority of multispecific (anti-PVA-1/PVA-2/PVA-12) supernates in the initial cultures arose from mixtures of hybridoma lines whose specificities segregated after cloning to obtain monoclonal cell lines. The monoclonal antibody which lacked anti-PVA-1 specificity (clone no. 18, table) did not protect mice against lethal infective challenge with the serotype-1 *Pseudomonas* strain. The remaining monoclonal antibodies showed various protective capacities against lethal serotype-1 pseudomonas infection, ranging from protection at a dilution of 1 in 300 (clone no. 11), to protection at dilutions of 1 in 10 000 (clones nos. 2, 3, 5, 6, 9, 10, 14 and 17). These highly protective antibodies...
were all IgG immunoglobulins, and included IgG1, IgG2b and IgG3 isotypes. The IgM antibodies were, in general, less protective than most of the IgG antibodies when ELISA titres were compared, but in some cases appeared to have the protective capacities approaching those of the IgG antibodies on a weight for weight comparison (table). Control culture supernates, from the NS-1 cell line and from an antibody-secreting hybrid cell line from an unrelated fusion, showed no protective capacity.

**Discussion**

Passive protection of mice against lethal infection by the homologous strain of *P. aeruginosa* serotype-1 was conferred by monoclonal antibodies that reacted with the immunising antigen PVA-1 in ELISA. Antibody from one clone (no. 18) failed to protect mice against infection. This antibody did not react with PVA-1 but cross-reacted with PVA-2 and PVA-12 in ELISA. Antibody from clone no. 4 cross-reacted with PVA-1, PVA-2 and PVA-12, and passively protected against infection with strain B.UK.1 although it had the lowest anti-PVA-1 ELISA titre of all in the series. The remaining antibodies were specific for PVA-1 alone in ELISA, and all were protective. The capacity of this series of monoclonal antibodies raised against *P. aeruginosa* serotype-1 antigen to cross protect against *P. aeruginosa* strains of other serotypes requires further investigation. Preliminary results have not indicated any protective capacity of the anti-PVA-1 monoclonal antibodies against infection with *P. aeruginosa* serotypes other than serotype-1.

There was no distinct relationship between protective capacity, ELISA titre, immunoglobulin isotype or immunoglobulin concentration. As a generalisation, the more highly protective antibodies, affording protection at dilutions greater than 1 in 10 000, tended to be of the IgG1 isotype which, conversely, tended to show low anti-PVA-1 titres in ELISA, and of the more highly protective antibodies, affording protection at dilutions greater than 1 in 10 000, tended to be of the IgG1 isotype which, conversely, tended to show low anti-PVA-1 titres in ELISA. As an example, clone no. 3 antibody is an IgG1 antibody, present at a concentration of 25 pg/ml in the culture supernate, showed low anti-PVA-1 titres in ELISA.

<table>
<thead>
<tr>
<th>Clone no. (ES-P-1S series)</th>
<th>Serotype specificity*</th>
<th>Ig isotype</th>
<th>Ig concentration in hybridoma culture supernate (µg/ml)</th>
<th>Anti-PVA-1 ELISA titre†</th>
<th>Protective titre‡ of antibody (µg of antibody/mouse)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>IgG3</td>
<td>90</td>
<td>1280</td>
<td>5000 (0.018)</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>IgG2b</td>
<td>46</td>
<td>80</td>
<td>&gt;10 000 (&gt;0.005)</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>IgG1</td>
<td>25</td>
<td>20</td>
<td>&gt;10 000 (&gt;0.003)</td>
</tr>
<tr>
<td>4</td>
<td>1, 12</td>
<td>IgG1</td>
<td>77</td>
<td>5</td>
<td>800 (0.096)</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>IgG1</td>
<td>30</td>
<td>160</td>
<td>&gt;10 000 (&gt;0.007)</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>IgG1</td>
<td>90</td>
<td>160</td>
<td>&gt;10 000 (&gt;0.009)</td>
</tr>
<tr>
<td>7</td>
<td>1</td>
<td>IgM</td>
<td>3-5</td>
<td>320</td>
<td>800 (0.004)</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td>IgM</td>
<td>4-6</td>
<td>640</td>
<td>1000 (0.005)</td>
</tr>
<tr>
<td>9</td>
<td>1</td>
<td>IgG3</td>
<td>33</td>
<td>320</td>
<td>&gt;10 000 (&gt;0.003)</td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>IgG3</td>
<td>94</td>
<td>640</td>
<td>&gt;10 000 (&gt;0.009)</td>
</tr>
<tr>
<td>11</td>
<td>1</td>
<td>IgG3</td>
<td>...</td>
<td>640</td>
<td>300 ...</td>
</tr>
<tr>
<td>12</td>
<td>1</td>
<td>IgG3</td>
<td>19</td>
<td>320</td>
<td>800 (0.024)</td>
</tr>
<tr>
<td>13</td>
<td>1</td>
<td>IgM</td>
<td>37</td>
<td>640</td>
<td>1000 (0.037)</td>
</tr>
<tr>
<td>14</td>
<td>1</td>
<td>IgM</td>
<td>35</td>
<td>320</td>
<td>&gt;10 000 (&gt;0.004)</td>
</tr>
<tr>
<td>15</td>
<td>1</td>
<td>IgM</td>
<td>23</td>
<td>320</td>
<td>700 (0.072)</td>
</tr>
<tr>
<td>16</td>
<td>1</td>
<td>IgM</td>
<td>106</td>
<td>640</td>
<td>700 (0.166)</td>
</tr>
<tr>
<td>17</td>
<td>1</td>
<td>IgG3</td>
<td>94</td>
<td>640</td>
<td>&gt;10 000 (&gt;0.009)</td>
</tr>
<tr>
<td>18</td>
<td>1, 12</td>
<td>IgG1</td>
<td>55</td>
<td>0</td>
<td>0 ...</td>
</tr>
</tbody>
</table>

* Determined by ELISA screen with the 16 serotype extracts (PVAs)
† End-point (last positive) dilution in ELISA.
‡ Dilution affording complete protection against lethal challenge with *P. aeruginosa* serotype-1 strain B.UK.1.

Table I. Characterisation of monoclonal antibodies produced after immunisation with *P. aeruginosa* serotype-1 antigen extract (PVA-1)
titres, indicating that the ELISA result does not predict protective capacity.

Passive protection and ELISA titres were not related to immunoglobulin concentrations. However, the vaccine antigens (PVA 1-16) are not homogeneous but are predominantly LPS (c. 95% by weight) with a minor proportion of outer-membrane proteins (OMP), and are not ideally suited for precise investigation of antibody specificities. We are currently investigating the chemical identity of the pseudomonas cell-wall antigens to which these different monoclonal antibodies bind (I.R. Poxton and G.R. Barclay, unpublished observations). Preliminary investigations by polyacrylamide gel electrophoresis antibodies and Western blotting confirm that PVA-1 specific monoclonal antibodies bind to epitopes of the polysaccharide O-antigen region of serotype-1 LPS, whereas cross-reactive monoclonal antibodies appear to bind to minor OMP (Poxton et al., 1985). The finding that anti-<i>P. aeruginosa</i> monoclonal antibodies with anti-LPS activity confer passive protection while those with anti-OMP activity do not agrees with the findings of Sawada et al. (1984). However, the protective capacities of the anti-LPS monoclonal antibodies of these authors were 10- to 100-fold less in a similar intraperitoneal protection model, and their IgM antibodies were more protective than their IgG antibodies.

Production of monoclonal antibodies against the other 15 PVAs is being done to determine their patterns of isotype production, specificity, cross-reactivity and passive protection properties against the 16 serotypes of <i>P. aeruginosa</i>. Preliminary findings indicate that monoclonal antibodies to different <i>P. aeruginosa</i> serotype extracts may differ considerably in these properties.

The hybridoma production work was supported by the Scottish Home and Health Department, Biomedical Research Committee, Grant K/MRS/50/C500 to Drs D.B.L. McClelland and K. James. We thank Dr D. Pepper for mouse IgG quantitation, Mr I. Hastings for mouse IgM quantification and for confirming Ig isotypes, and Professor G.D. Chisholm and Dr J.D. Cash for their encouragement.

REFERENCES


Jones R J, Roe E A 1975 Protective properties and haemagglutinins in serum from humans and in serum injected from mice injected with a new polyvalent pseudomonas vaccine. <i>British Journal of Experimental Pathology</i> 56:34–43.


Roe E A, Jones R J 1983 Immunization of burned patients against <i>Pseudomonas aeruginosa</i> infection at Safdarjang Hospital, New Dehli. <i>Reviews of Infectious Diseases Suppl</i> 5:5922–5930.